Kazia Therapeutics (KZIA) Debt to Equity (2018 - 2025)

Kazia Therapeutics (KZIA) has disclosed Debt to Equity for 5 consecutive years, with -$0.38 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Debt to Equity fell 499.55% year-over-year to -$0.38, compared with a TTM value of -$0.38 through Jun 2025, down 499.55%, and an annual FY2025 reading of -$0.38, down 499.55% over the prior year.
  • Debt to Equity was -$0.38 for Q2 2025 at Kazia Therapeutics, down from -$0.06 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.15 in Q2 2023 and bottomed at -$0.38 in Q2 2025.
  • Average Debt to Equity over 4 years is -$0.1, with a median of -$0.08 recorded in 2022.
  • The sharpest move saw Debt to Equity soared 250.89% in 2023, then tumbled 499.55% in 2025.
  • Year by year, Debt to Equity stood at -$0.1 in 2022, then skyrocketed by 250.89% to $0.15 in 2023, then tumbled by 142.47% to -$0.06 in 2024, then plummeted by 499.55% to -$0.38 in 2025.
  • Business Quant data shows Debt to Equity for KZIA at -$0.38 in Q2 2025, -$0.06 in Q2 2024, and $0.15 in Q2 2023.